Precise and Accurate CHN Data from Low Weight Samples
A new report from Exeter Analytical demonstrates how the Model 440 CHN Analyser provides precise and accurate determination of percentage carbon, hydrogen and nitrogen on samples as small as 0.3 mg.
Using Atropine (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate) as the test compound the Model 440 produced data from 0.3 mg samples which only varied within +/- 0.12% of the theoretical CHN values. In environments such as pharmaceutical research and synthetic chemistry laboratories, where the weight of new compounds for analytical purposes is often limited, the ability to reliably generate reliable CHN data on sub 0.5 milligram samples is highly valuable.
The Exeter Analytical Model 440 is a static combustion CHN Elemental Analyser, with a unique horizontal furnace design, which enables easy removal of sample residue between each analysis. Because the Model 440 is able to effectively eliminate troublesome residue build-up, its gas flow characteristics are superior to other CHN Analysers leading to longer-term calibration stability, as well as enhanced accuracy and precision for measured sample data.
Because the Model 440 provides complete control over combustion parameters it is able to reproducibly achieve 100% combustion with the widest range of sample types. Through incorporation of extensive automation in the Model 440 and intuitive software – the percentage Carbon (C), Hydrogen (H) and Nitrogen (N) in samples can be determined in as little as 5 minutes.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...